Overview

CART-PSMA Cells for Advanced Prostate Cancer

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced prostate cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Nova Therapeutics LLC

Collaborator:

Chinese PLA General Hospital